PW Medtech Group Limited disclosed that it bought back 473,000 ordinary shares on 2 September 2026 via the Hong Kong Stock Exchange at prices ranging between HKD 0.90 and HKD 0.92, spending HKD 0.43 million.

Including this latest transaction, the company has repurchased 2.89 million shares since the current mandate became effective on 26 June 2026. The repurchased shares, all pending cancellation, equal 0.20 % of the total issued share capital on the mandate date and have cost approximately HKD 3.00 million at an average price of HKD 1.04 per share.

Following the buy-backs, PW Medtech’s issued share capital remains unchanged at 1.43 billion shares because the repurchased shares have not yet been cancelled. The board is authorised to repurchase up to 144.29 million shares, leaving about 141.40 million shares—roughly 98 % of the mandate—still available.

In line with Hong Kong listing rules, the company is subject to a moratorium on new share issues until 2 October 2026.